PERNIX THERAPEUTICS HOLDINGS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation
Amortization of intangibles
Amortization of deferred financing costs
Accretion expense
Interest accretion of notes receivable
PIK interest payable
Deferred income benefit
Gain on sale of investment
Loss on disposal of fixed assets
Loss from the operations of the joint venture
Stock compensation expense
Fair market value change in derivative liability
Fair market value change in contingent consideration
Gain on contingent consideration and put right
Issuance of stock for inducement
Gain from legal settlement
Gain from exchange of debt
Gain from sale of non-core assets
Impairment of fixed assets and intangibles
Loss on sale of PML (including impairment)
Expense for stock options issued in exchange for services
Cancellation of ParaPRO stock options in connection with termination of contract
Decrease (increase) in operating assets (excluding effect of acquisitions):
Accounts receivable
Income taxes
Inventory
Prepaid expenses and other assets
Increase (decrease) in operating liabilities (excluding effect of acquisitions):
Accounts payable and accrued expenses
Accrued expenses and personnel expenses
Accrued allowances
Arbitration award
Interest payable
Other liabilities
Net cash used in operating activities

Cash flows from investing activities:
Acquisitions
Proceeds from sale of investment
Acquisition of Cypress Pharmaceuticals ("Cypress")
Payments received on notes receivable
Proceeds from sale of PML
Proceeds from sale of certain Cypress assets
Other intangibles
Proceeds from sale of non-core assets
Purchase of software and equipment
Net cash provided by (used in) investing activities

Cash flows from financing activities:
Proceeds from issuance of Convertible Notes
Net payments on revolving credit facility
Payments on Treximet Secured Notes
Net proceeds from Delayed Draw Term Loan
Payments for financing costs
Proceeds from credit facility, net of capitalized loan costs
Payment of consent fee
Payments on Exchangeable Notes
Net drawdowns (payments) on credit facilities
Payments on mortgages and capital leases
Proceeds from issuance of common stock, net of tax and costs
Shares withheld for the payment of taxes
Cash acquired in connection with acquisition of Somaxon
Payments on original Midcap Loan
Payments on term loan
Stock issuance costs
Payments on contracts payable
Proceeds from issuance of stock in additional offering, net of issuance costs of $846 for the year ended December 31, 2012
Proceeds from issuance of common stock, net of tax
Tax benefit on stock-based awards
Net cash provided by (used in) financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period

Cash paid for income taxes
Interest paid during the period
Acquisition of product licenses - contract payable balance
Accrued bonus paid in unrestricted stock
Accrued severance paid in restricted common stock
Acquisition of Cypress and Somaxon - Purchase price adjustment (see Note 4)
Acquisition of Somaxon - Fair value of common stock
Acquisition of Treximet - warrants issued to Pozen
Warrants issued to Frontline in connection with the issuance of the February 2014 Convertible Notes
Acquisition of Cypress - fair value of common stock
Acquisition of GSL - liabilities assumed

Comments